Charts Week Month
Heat map Market Overview
Sentiment Sectors ETFs
Earnings News Earnings Movers The Drift Pivots
The Big Picture Breakouts Full Earnings News
Investor Services

Earnings are the driver of stock prices and the right earnings information can help longer-term investors significantly outperform the overall stock market.

The Whisper Report ® A look at upcoming earnings from both a top-down and bottom-up basis. Grades Stocks with A+ Earnings Whisper Grades Have Significantly Outperformed the Stock Market. Call Summaries Conference call summaries. AI Call Analysis AI Conference call analysis. Earnings Daily earnings results. Guidance Daily earnings guidance from companies. Reactions Earnings Screener Short Interest Report When the short trade becomes crowded.
Trader Service

Short-term earnings trading tools built around expectations, sentiment, quantitative studies, volatility, and post-earnings drift.

Trading Strategy The current strategy based on a broad market analysis and data. Earnings Whisper Plays Combining research, sentiment, quantitative studies, and technical analysis for short-term trades. Scores Identifying the likely Earnings Announcement Premium. Power Ratings Earnings with enough power for a short-term Post-Earnings Announcement Drift. Whisperings ^TM Whisperings are comments from analysts about upcoming earnings releases. AI Call Rankings Find which companies had the strongest or weakest conference calls. Option Trades Volatility Options Activity Unusual options activity around earnings. Setups Unusual options activity around earnings. Reversals Unusual options activity around earnings. Spikes Unusual options activity around earnings.
Dashboard

AYTU Aytu BioPharma, Inc.

Aytu BioPharma Missed Consensus Estimates

Wednesday, May 13, 2026 · 12:00 AM ET

Aytu BioPharma (AYTU) reported a loss of $0.53 per share on revenue of $12.41 million for the fiscal third quarter ended March 2026. The consensus estimate was a loss of $0.31 per share on revenue of $12.00 million. The company missed consensus estimates by 70.97% while revenue fell 32.74% compared to the same quarter a year ago.

Aytu BioPharma is a specialty pharmaceutical company with a growing commercial portfolio of prescription therapeutics and consumer health products.

Earnings Whisper Grade —

Power Rating—

Reported Earnings

($0.53)

Earnings Whisper^®

—

Consensus Estimate

($0.31)

Earnings Surprise

Earnings Growth

Reported Revenue

$12.41M

Revenue Estimate

$12.00M

Revenue Surprise

Revenue Growth